Clinical effectiveness is of the finest tools to evaluate treatment success and is combined of 3 elements: treatment effectivity, side effect profile and patient compliance. Since the 3 main PDE5i's differ in their molecular structure, therapeutic profile and pharmacokinetics, it seems logical to assume that combining 2 different PDE5i's at lower dosage each may be beneficial in comparison to a single PDE5i maximal dose therapy. The aim of this study is to compare the clinical effectiveness of combination therapy (2 lower-dose PDE5i's) versus single maximal dose PDE5i therapy.
This will be a prospective, randomized, 3-arm parallel trial on 60 males with erectile dysfunction (ED) that have never been exposed to PDE5i therapy (naïve patients) will be enrolled. In each group, every patient will receive three treatment regimes (Viagra®50mg \& Cialis®10mg, Viagra®100mg, Cialis®20mg), in different sequences of administration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
30
4 tablets for on demand use
4 tablets on demand
4 tablets on demand
Rambam Health Care Campus
Haifa, Israel
International Index of Erectile Function-Erectile Dysfunction (IIEF-ED) Domain Score
At each visit after use of different treatment each time
Time frame: Every visit- altogether 3 months
Erection Hardness Scale
At each visit after use of different treatment each time
Time frame: Each visit- altogether 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.